Cantor Fitzgerald Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Eupraxia Pharmaceuticals today and set a price target of $19.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kluska covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Disc Medicine, and Eupraxia Pharmaceuticals. According to TipRanks, Kluska has an average return of 24.1% and a 46.01% success rate on recommended stocks.
In a report released on February 23, Bloom Burton also initiated coverage with a Buy rating on the stock with a $14.00 price target.
Based on Eupraxia Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of C$8.76 million. In comparison, last year the company had a GAAP net loss of C$5.94 million
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPRX in relation to earlier this year.
Read More on TSE:EPRX:
Disclaimer & DisclosureReport an Issue
- Eupraxia Pharmaceuticals Raises US$63.2 Million in February 2026 Equity Offering to Advance GI Pipeline
- Eupraxia Pharmaceuticals Raises US$63.2 Million to Advance GI Pipeline and Commercial Readiness
- Eupraxia Pharmaceuticals Launches Cross-Border Equity and Warrant Offering Under New Underwriting Pact
- Eupraxia Pharmaceuticals 6.4M share Spot Secondary priced at $7.00
- Eupraxia Raises US$55 Million to Accelerate EP-104GI and GI Pipeline
